Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma.

ABSTRACT: Medulloblastoma is the most common malignant brain tumor in children. It has WNT-driven, SHH-driven/TP53 mutant, SHH-driven/TP53 wildtype, and non-WNT/non-SHH subgroups. MAGMAS (Mitochondrial Associated Granulocyte Macrophage colony-stimulating factor Signaling molecules) encodes a mitochondrial import inner membrane translocase subunit and is responsible for the translocation of matrix proteins across the inner membrane. We previously reported that a small molecule MAGMAS inhibitor, BT9, decreases cell proliferation, migration, and oxidative phosphorylation in adult glioblastoma cell lines. The aim of our study was to investigate whether the chemotherapeutic effect of BT9 can be extended to pediatric medulloblastoma.

Methods

DAOY (SHH driven/tp53 mutant) and D425 (non-SHH group 3)

SUBMITTER: Motahari Z 

PROVIDER: S-EPMC11495579 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature